Evidence for noradrenergic mediation of the oxotremorine-induced increase in acetylcholine content in rat hippocampus.
D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001596:Benzylamines / Q000494:pharmacology; D005406:Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide / Q000494:pharmacology; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D002802:Cholinesterases / Q000378:metabolism; D005260:Female; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism*; D008711:Metergoline / Q000494:pharmacology; D008781:Methyltyrosines / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism*; D010095:Oxotremorine / Q000494:pharmacology*; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D012701:Serotonin / Q000378:metabolism*; D019805:alpha-Methyltyrosine
D001596:Benzylamines; D008781:Methyltyrosines; D010643:Phenoxybenzamine; D008711:Metergoline; D005406:Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; D012701:Serotonin; D010095:Oxotremorine; D019805:alpha-Methyltyrosine; D001285:Atropine; D011433:Propranolol; D002795:Choline O-Acetyltransferase; D002802:Cholinesterases; D000109:Acetylcholine; C012102:DSP 4; D009638:Norepinephrine